HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS)

Aligos Therapeutics (NASDAQ:ALGS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $75.00 price objective on the stock.

Aligos Therapeutics Stock Performance

NASDAQ:ALGS opened at $9.03 on Wednesday. The company has a 50-day moving average of $10.69 and a 200-day moving average of $13.65. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $30.00. The company has a market capitalization of $705.33 million, a price-to-earnings ratio of -7.05 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The firm had revenue of $1.06 million during the quarter. During the same quarter in the prior year, the business earned ($10.75) EPS. Sell-side analysts forecast that Aligos Therapeutics will post -8.2 EPS for the current year.

Institutional Trading of Aligos Therapeutics

Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares in the last quarter. Armistice Capital LLC lifted its holdings in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares during the last quarter. Finally, Opaleye Management Inc. boosted its position in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).